Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of two locations we draw on the diverse talents of a 500-strong team. More>

Lemtrada®▼ (alemtuzumab) 12mg IV, a new treatment for adults with active relapsing remitting multiple sclerosis (RRMS), is recommended by NICE and now available in England

The National Institute for Health and Care Excellence (NICE), has announced today the final approval of Lemtrada as an option for treating adults with active RRMS, within its marketing authorisation. Patients with RRMS will now be able to access this new treatment on the NHS. More>

Genzyme Supports International Pompe Day 2014

Genzyme, a Sanofi company, today announces its support of International Pompe Day, the first time the annual event is being held, to highlight awareness of this rare neuromuscular disease. The inaugural International Pompe Day 2014 is being marked with the theme “Together We Are Stronger”. More>

Genzyme Supports Rare Disease Day 2014

Genzyme, a Sanofi company, today announces its support of Rare Disease Day to highlight rare diseases as an important public health issue. Genzyme joins patients, healthcare providers and patient organisations in the UK and Ireland, and around the world to raise awareness and better understanding of these diseases. More>